Lantern Pharma receives Rare Pediatric Disease and Orphan Drug designations for LP-184 in ATRT

Lantern Pharma Inc.

FDA grants Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 to treat atypical teratoid rhabdoid tumor (ATRT).
LP-184 is the third Lantern program to receive Orphan Drug Designation; prior designations for pancreatic cancer and malignant glioma.
Rare Pediatric Disease Designation may qualify Lantern for a Priority Review Voucher upon FDA approval of LP-184.
ATRT is an aggressive CNS tumor; nearly 90% of pediatric cases involve SMARCB1 mutations, which LP-184 targets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.